Compare ALNY & TEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNY | TEAM |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 43.3B |
| IPO Year | 2004 | 2015 |
| Metric | ALNY | TEAM |
|---|---|---|
| Price | $322.95 | $86.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 24 |
| Target Price | ★ $474.42 | $206.42 |
| AVG Volume (30 Days) | 1.6M | ★ 6.5M |
| Earning Date | 02-12-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | $3,210,070,000.00 | ★ $5,759,928,000.00 |
| Revenue This Year | $70.40 | $23.46 |
| Revenue Next Year | $44.32 | $18.37 |
| P/E Ratio | $979.16 | ★ N/A |
| Revenue Growth | ★ 53.24 | 20.13 |
| 52 Week Low | $205.87 | $88.51 |
| 52 Week High | $495.55 | $326.00 |
| Indicator | ALNY | TEAM |
|---|---|---|
| Relative Strength Index (RSI) | 29.08 | 20.67 |
| Support Level | $333.00 | $88.51 |
| Resistance Level | $355.49 | $97.00 |
| Average True Range (ATR) | 11.22 | 7.67 |
| MACD | -1.16 | -2.66 |
| Stochastic Oscillator | 8.92 | 2.98 |
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.